Hendrik Peter Scholl sold $83k of BLTE
Chief Medical Officer at BELITE BIO, INC. 500 shares at an average of $165.32, traded Oct 1, 2026, filed Oct 5, 2026.
Score components
- +15RoleOfficer
- +9Trade size$83k at market
- 0Share of holdings soldSold 3.3% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-414643, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -200 | $163.63 | $33k | 14,800 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -24 | $164.64 | $3,951 | 14,776 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -120 | $165.49 | $20k | 14,656 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -50 | $166.44 | $8,322 | 14,606 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -78 | $167.59 | $13k | 14,528 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -12 | $168.21 | $2,019 | 14,516 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -14 | $169.36 | $2,371 | 14,502 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -2 | $170.02 | $340 | 14,500 | 10 d ago |
Related signals
Other insiders at BELITE BIO, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 55Moderate | BELITE BIO, INC | Hao-Yuan Chuang Chief Financial Officer | $13M 67,395 shares | -72% | |
| 58Moderate | BELITE BIO, INC | Yu-Hsin Lin Chief Executive Officer | $19M 100,435 shares | -59% | |
| 21Weak | BELITE BIO, INC | Yu-Hsin Lin Chief Executive Officer | $66k 365 shares | -0% | |
| 18Weak | BELITE BIO, INC | Hao-Yuan Chuang Chief Financial Officer | $66k 367 shares | -0% | |
| 50Moderate | BLTEsell BELITE BIO, INC | Hendrik Peter Scholl Chief Medical Officer | $1.5M 10,000 shares | -40% | |
| 50Moderate | BLTEsell BELITE BIO, INC | Hendrik Peter Scholl Chief Medical Officer | $1.4M 10,000 shares | -29% | |
| 25Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $102k 666 shares | -100% | |
| 26Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $154k 1,000 shares | -60% | |
| 16Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $156k 1,000 shares | -38% | |
| 16Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $156k 1,000 shares | -27% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.